Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antisense
Biotech
AusperBio adds $120M series C to push hep B drug through ph. 3
AusperBio has raised $120 million to advance its oligonucleotide therapy for chronic hep B through phase 3 and hopefully on to commercialization.
Marissa Russo
Aug 28, 2026 10:26am
AAIC: Biogen bolsters hopes for pivotal anti-tau push
Jul 14, 2026 9:15am
Ionis bags $30M from Recordati for ex-US rare disease rights
Jun 25, 2026 6:59am
Biogen advances Alzheimer’s tau program despite midphase miss
May 14, 2026 8:35am
Biogen links up with Alloy platform to boost ASO drug development
Apr 7, 2026 6:00am
GSK pays $17.5M for CAMP4 regulatory RNA deal
Dec 18, 2025 7:00am
